PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-7.59%
Both companies show declining cash positions (-7.59% vs TRAW's -17.52%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-7.59%
Below half of TRAW's -17.52%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of TRAW's 32.34%. David Dodd sees a leaner approach to short-term items.
-8.57%
0.5-0.75x TRAW's -16.11%. Martin Whitman might see risk if this hampers near-term financial flexibility.
-5.56%
Below half TRAW's -15.38%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.97%
Higher Long-Term Investments Growth compared to TRAW's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-4.96%
Below half of TRAW's -14.81%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-8.43%
0.5-0.75x TRAW's -16.11%. Martin Whitman worries about slower asset growth than competitor. Is it strategy or constraint?
-2.42%
Less than half of TRAW's -8.60%. David Dodd sees a more disciplined AP approach or lower volume.
3.64%
Higher Short-Term Debt Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-101.55%
Both TRAW and the company show zero Deferred Revenue (Current) Growth.
-3.64%
1.1-1.25x TRAW's -2.98%. Bill Ackman wonders if the firm is incurring more one-time charges than competitor.
-2.05%
Less than half of TRAW's -4.69%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
95.51%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to TRAW's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.32%
Less than half of TRAW's -1.97%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-0.65%
Less than half of TRAW's -4.07%. David Dodd sees far fewer liability expansions relative to competitor.
3.70%
Higher Common Stock (Book Value) Growth compared to TRAW's zero value, indicating worse performance.
-2.84%
≥ 1.5x TRAW's -0.87%. David Dodd sees higher yoy retained profits than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-16.53%
0.5-0.75x TRAW's -26.49%. Martin Whitman is wary of lagging equity growth vs. competitor.
-8.43%
0.5-0.75x TRAW's -16.11%. Martin Whitman sees underexpansion or possible missed opportunities.
0.97%
Higher Total Investments Growth compared to TRAW's zero value, indicating better performance.
-4.43%
Higher Total Debt Growth compared to TRAW's zero value, indicating worse performance.
7.68%
Less than half of TRAW's 17.52%. David Dodd sees better deleveraging or stronger cash buildup than competitor.